A story in the Irish Independent says Pfizer intends to sell one of its Irish plants, in large part because of declining revenues from its anti-cholesterol drug Lipitor.
Sales of Lipitor, a former blockbuster for the company, have been plummeting recently because its patent expired, opening it up to competition from generics. The drug has also been the subject of some recent health concerns.
The U.S. Food and Drug Administration has added ...
continue reading...